NCT06881238 Impact of Hepatitis B Virus on Inflammatory Bowel Disease
| NCT ID | NCT06881238 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tanta University |
| Condition | Inflammatory Bowel Disease (IBD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 162 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2025-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 162 participants in total. It began in 2024-12-01 with a primary completion date of 2025-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational retrospective study is to assess the impact of hepatitis B virus (HBV) infection on the clinical course and outcomes of inflammatory bowel disease (IBD) in Egyptian patients. Researchers will compare the IBD extent, location, severity, and behavior between IBD patients with and without HBV infection. Participants will be subjected to history-taking (history of hospital admission and disease flare, surgical history, medication history, follow-up duration, and mortality), clinical examination, laboratory investigations, abdominal ultrasonography, and endoscopic examination.
Eligibility Criteria
Inclusion Criteria: * Male or female patients older than 18 years. * Patients with IBD are diagnosed by clinical, radiological, endoscopic, and histological criteria. Exclusion Criteria: * Patients aged \< 18 years * Unwilling to participate in our study
Contact & Investigator
Nabila A Elgazzar, MD
STUDY DIRECTOR
Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University
Frequently Asked Questions
Who can join the NCT06881238 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Inflammatory Bowel Disease (IBD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06881238 currently recruiting?
Yes, NCT06881238 is actively recruiting participants. Contact the research team at rania.elkafoury@med.tanta.edu.eg for enrollment information.
Where is the NCT06881238 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT06881238 clinical trial?
NCT06881238 is sponsored by Tanta University. The principal investigator is Nabila A Elgazzar, MD at Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University. The trial plans to enroll 162 participants.